on Biophytis (EPA:ALBPS)
Biophytis Expands Bond Facility with Hexagon Capital to €2 Million
On February 27, 2026, Biophytis SA announced significant amendments to its bond agreement with Hexagon Capital Fund. The company's bond financing ceiling increased from €1 million to €2 million. Additionally, the bond subscription period extends to December 31, 2027, enhancing Biophytis' financial structure and cash runway by four months.
Biophytis has a €1,350,000 drawing capacity left, having used €650,000 already. Bonds bear a 12% interest, redeemable bi-monthly in cash or shares in case of default. The shares are priced at €0.05654, a 110% premium over the recent closing price.
CEO Stanislas Veillet expressed confidence in progressing clinical development in obesity and sarcopenia. Hexagon's Jean-Philippe Cridlig reiterated support for Biophytis' promising pipeline addressing high unmet medical needs.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news